EUVIMEDEUVIMED entdecken
Crossref

The Association Between [ 68 Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

Mengxia Chen, Yao Fu, Shan Peng, Shiming Zang, Shuyue Ai, Junlong Zhuang, Feng Wang, Xuefeng Qiu, Hongqian Guo

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.122.265368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Mengxia Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our previous study found that the prostate-specific membrane antigen (PSMA) PET/CT response of primary prostate cancer (PCa) to neoadjuvant therapy can predict the pathologic response. This study was designed to investigate the association between [68Ga]PSMA PET/CT changes and biochemical progression-free survival (bPFS) in high-risk patients who underwent neoadjuvant therapy before radical prostatectomy (RP).

Methods

Seventy-five patients with high-risk PCa in 2 phase II clinical trials who received neoadjuvant therapy before RP were included. The patients received androgen deprivation therapy plus docetaxel (n = 33) or androgen deprivation therapy plus abiraterone (n = 42) as neoadjuvant treatment. All patients had serial [68Ga]PSMA PET/CT scans before and after neoadjuvant therapy. Age, initial prostate-specific antigen level, nadir prostate-specific antigen level before RP, tumor grade at biopsy, treatment regimen, clinical T stage, PET imaging features, pathologic N stage, and pathologic response on final pathology were included for univariate and multivariate Cox regression analyses to identify independent predictors of bPFS.

Results

With a median follow-up of 30 mo, 18 patients (24%) experienced biochemical progression. Multivariate Cox regression analyses revealed that only SUVmax derived from posttreatment [68Ga]PSMA PET/CT and pathologic response on final pathology were independent factors for the prediction of bPFS, with hazard ratios of 1.02 (95% CI, 1.00-1.04; P = 0.02) and 0.12 (95% CI, 0.02-0.98; P = 0.048), respectively. Kaplan-Meier analysis revealed that patients with a favorable [68Ga]PSMA PET/CT response (posttreatment SUVmax < 8.5) or a favorable pathologic response (pathologic complete response or minimal residual disease) had a significantly lower rate of 3-y biochemical progression.

Conclusion

Our results indicated that [68Ga]PSMA PET/CT response was an independent risk factor for the prediction of bPFS in patients with high-risk PCa receiving neoadjuvant therapy and RP, suggesting [68Ga]PSMA PET/CT to be an ideal tool to monitor response to neoadjuvant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansGallium RadioisotopesPositron Emission Tomography Computed TomographyNeoadjuvant TherapyAndrogen AntagonistsAndrogens

Stichwörter der Autor:innen

[68Ga]PSMA PET/CTbiochemical progressionneoadjuvant therapypredictionprostate cancer

Substanzen

Prostate-Specific AntigenGallium RadioisotopesAndrogen AntagonistsAndrogens

Autor:innen und Institutionen

  • Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Institute of Urology, Nanjing University, Nanjing, China.
  • Department of Pathology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China; and.
  • Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China; dr.ghq@nju.edu.cn xuefeng_qiu@nju.edu.cn.

Zitieren

APA

Chen, M., Fu, Y., Peng, S., Zang, S., Ai, S., Zhuang, J., Wang, F., Qiu, X., & Guo, H. (2023). The Association Between [ 68 Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.265368

Vancouver

Chen M, Fu Y, Peng S, Zang S, Ai S, Zhuang J, et al. The Association Between [ 68 Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.122.265368

BibTeX
@article{Chen2023,
  author = {Chen, Mengxia and Fu, Yao and Peng, Shan and Zang, Shiming and Ai, Shuyue and Zhuang, Junlong and Wang, Feng and Qiu, Xuefeng and Guo, Hongqian},
  title = {The Association Between [ 68 Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.122.265368}
}
Kostenlos starten →